A5075418258- Cancer Research and Treatments
- Glycosylation and Glycoproteins Research
- Escherichia coli research studies
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Biochemical and Molecular Research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- CRISPR and Genetic Engineering
- RNA and protein synthesis mechanisms
- Digestive system and related health
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Transgenic Plants and Applications
- Cutaneous Melanoma Detection and Management
- Lipid metabolism and biosynthesis
- Complement system in diseases
- Nonmelanoma Skin Cancer Studies
- Extracellular vesicles in disease
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Bacterial Genetics and Biotechnology
- interferon and immune responses
- Peroxisome Proliferator-Activated Receptors
- Medical Malpractice and Liability Issues
University Hospital Regensburg
2021-2025
University Medical Center
2024
Leibniz Institute for Immunotherapy
2022-2024
Klinikum rechts der Isar
2016-2022
Technical University of Munich
2016-2022
Innsbruck Medical University
2020
Universität Innsbruck
2020
Abstract Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and efficacy data belumosudil from 5 German/Swiss transplant centers. A total 33 adult patients (median age 59 years) with moderate ( n = 2) or severe 31) cGvHD were treated on individual request due to lack EMA approval. The patient cohort had long history 44 months) was heavily...
The B-subunit of the bacterial Shiga toxin (STxB), which is nontoxic and has low immunogenicity, can be used for tumor targeting breast, colon, pancreatic cancer. Here, we tested whether human gastric cancers, are among most aggressive entities, express cellular receptor toxin, glycosphingolipid globotriaosylceramide (Gb3/CD77). majority cases showed an extensive staining Gb3 (36/50 cases, 72%), as evidenced on tissue sections surgically resected specimen. expression was detected independent...
The main cellular receptors of Shiga toxins (Stxs), the neutral glycosphingolipids (GSLs), globotriaosylceramide (Gb3Cer/CD77) and globotetraosylceramide (Gb4Cer), are significantly upregulated in about half human colorectal carcinomas (CRC) other cancers. Therefore, conjugates exploiting Gb3Cer/Gb4Cer-binding B subunit Stx (StxB) have attracted great interest for both diagnostic adjuvant therapeutic interventions. Moreover, fucosylated GSLs were recognized as potential tumor-associated...
Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result of disseminated intravascular coagulation (DIC) and liver dysfunction. We investigated incidence risk factors for in 41 consecutive adult patients hematologic malignancies (median age 69 years, range 38-83 years) receiving CAR between January 2020 May 2023 at...
Tumor-derived extracellular vesicles (EVs) have been associated with immune evasion and tumor progression. We show that the RNA-sensing receptor RIG-I within cells governs biogenesis immunomodulatory function of EVs. Cancer-intrinsic activation releases EVs, which mediate dendritic cell maturation T antitumor immunity, synergizing checkpoint blockade. Intact RIG-I, autocrine interferon signaling, GTPase Rab27a in are required for immunostimulatory Active intrinsic signaling composition EV...
Durable clinical responses to immune checkpoint inhibitors (ICI) are limited a minority of patients, and molecular pathways that modulate their efficacy remain incompletely defined. We have recently shown activation the innate RNA-sensing receptor RIG-I associated apoptotic tumor cell death can facilitate immunosurveillance -therapy, but mechanism drives its immunogenicity remained unclear. here show intratumoral activity pore-forming protein gasdermin E (GSDME) links active signaling in...
Changes in the intestinal microbiome and microbiota-derived metabolites predict clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we report that desaminotyrosine (DAT), a product of bacterial flavonoid metabolism, correlates with improved overall survival reduced relapse rates allo-HSCT patients. In preclinical mouse models, treatment synthetic DAT prevents graft-versus-host disease by protecting barrier promoting regeneration contributes to...
Emerging data have highlighted a correlation between microbiome composition and cancer immunotherapy outcome. While commensal bacteria their metabolites are known to modulate the host environment, contradictory effects lack of mechanistic understanding impede translation microbiome-based therapies into clinic. In this study, we demonstrate that abundance metabolite pentanoate is predictive for survival chimeric antigen receptor (CAR) T cell patients in two independent cohorts. Its...
Chronic graft-versus-host disease (cGVHD) is the leading cause of late nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and defined by 8 diagnostic target organs. Recently, provisional criteria for atypical manifestations cGVHD that include in nonclassic organs as well National Institutes Health (NIH)-defined organs, were proposed a NIH task force. Little known about incidence, risk factors, impact on survival cGVHD, however. The aim present...
The complement factor H antibody (CFH-Ab)-associated hemolytic uremic syndrome (HUS) forms a distinct subgroup within the complement-mediated HUS disease spectrum. autoimmune nature of this implies potential benefit targeted immunosuppressive therapy. Data on long-term outcome are scarce.This observational study evaluates clinical 19 pediatric CFH-Ab patients from onset until their 5-year follow-up.All but one relapse occurred during first 2 years, and who had no 6 months were relapse-free...
Abstract The B subunit of bacterial Shiga toxin (STxB) is nontoxic and has low immunogenicity. Its receptor, the glycosphingolipid Gb3/CD77, overexpressed on cell surface human colorectal cancer. We tested whether genetic porcine models, closely resembling anatomy pathophysiology, can be used to exploit tumor-targeting potential STxB. In accordance with findings cancer, pig model APC1311 bound STxB in tumors, but not normal colon or jejunum, except for putative enteroendocrine cells. primary...
<div>Abstract<p>The B subunit of bacterial Shiga toxin (STxB) is nontoxic and has low immunogenicity. Its receptor, the glycosphingolipid Gb<sub>3</sub>/CD77, overexpressed on cell surface human colorectal cancer. We tested whether genetic porcine models, closely resembling anatomy pathophysiology, can be used to exploit tumor-targeting potential STxB. In accordance with findings cancer, pig model <i>APC<sup>1311</sup></i> bound STxB in tumors,...
Abstract Plastic surgeons are trained to perform a wide repertoire of surgeries—ranging from standard local procedures highly specialized operations. Therefore, plastic treat plethora clinical presentations and address multiple patient needs. Their daily workflow is increasingly entwined with legal topics. The concrete interpretation falls within the remit experts. However, by understanding basics selected surgical procedures, may generate synergies in care practice. situation be elucidated...
Supplementary Data from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
<div>Abstract<p>The B subunit of bacterial Shiga toxin (STxB) is nontoxic and has low immunogenicity. Its receptor, the glycosphingolipid Gb<sub>3</sub>/CD77, overexpressed on cell surface human colorectal cancer. We tested whether genetic porcine models, closely resembling anatomy pathophysiology, can be used to exploit tumor-targeting potential STxB. In accordance with findings cancer, pig model <i>APC<sup>1311</sup></i> bound STxB in tumors,...
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Data from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma